Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 19Lymphoma 19Lymphoma, Mantle-Cell 17Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Lymphoma, Non-Hodgkin 9Recurrence 6Hodgkin Disease 6Waldenstrom Macroglobulinemia 5Neoplasms 3Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Sezary Syndrome 1Proteostasis Deficiencies 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 12Biopsy 10Specimen Handling 9Whole-Body Irradiation 7Magnetic Resonance Spectroscopy 7pembrolizumab 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Etoposide 6fludarabine 5duvelisib 5Brentuximab Vedotin 5ruxolitinib 4fludarabine phosphate 4Vincristine 4Prednisone 4Doxorubicin 4Cytarabine 410-propargyl-10-deazaaminopterin 4romidepsin 3X-Rays 3Mycophenolic Acid 3Immunoglobulin G 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Disulfides 3Carmustine 3venetoclax 2tazemetostat 2sodium-iodide symporter 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Bendamustine Hydrochloride × 1 year × Clear all
NCT07225985 2026-05-11

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡